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The diagnosis of chronic traumatic encephalopathy (CTE) upon autopsy in a growing number
of athletes and soldiers alike has resulted in increased awareness, by both the scien-
tific/medical and lay communities, of the potential for lasting effects of repetitive traumatic
brain injury. While the scientific community has come to better understand the clini-
cal presentation and underlying pathophysiology of CTE, the diagnosis of CTE remains
autopsy-based, which prevents adequate monitoring and tracking of the disease. The lack
of established biomarkers or imaging modalities for diagnostic and prognostic purposes
also prevents the development and implementation of therapeutic protocols. In this work
the clinical history and pathologic findings associated with CTE are reviewed, as well as
imaging modalities that have demonstrated some promise for future use in the diagnosis
and/or tracking of CTE or repetitive brain injury. Biomarkers under investigation are also
discussed with particular attention to the timing of release and potential utility in situa-
tions of repetitive traumatic brain injury. Further investigation into imaging modalities and
biomarker elucidation for the diagnosis of CTE is clearly both needed and warranted.
Keywords: chronic traumatic encephalopathy, CTE,TBI, biomarkers, imaging
INTRODUCTION
Increasing awareness by both medical professionals and the
lay community concerning the potential long-term effects of
repetitive traumatic brain injury, such as chronic traumatic
encephalopathy (CTE) and cognitive impairment (Guskiewicz
et al., 2005; Gavett et al., 2010; Daneshvar et al., 2011), has led
to the identification of a need for improved diagnostic and prog-
nostic tests. Investigators have focused primarily on the use of
various imaging modalities and development of blood- or CSF-
based biomarkers. In the following sections we attempt to briefly
review findings associated with CTE diagnosis, proposed disease
pathophysiology, and how these findings may potentially relate to
imaging and/or biomarker discovery.
EPIDEMIOLOGY AND CLINICAL PRESENTATION
Exposure to repetitive mild traumatic brain injury (mTBI) is a
common occurrence in athletes on the playing field and soldiers
on the battlefield. In fact, playing American football at higher levels
results in documented exposure of up to 1400 impacts per season
for select positions such as linemen with some players involved
in both offense and defense sustaining nearly 2000 impacts (Stern
et al., 2011). Similarly, mTBI has been identified as the most com-
mon combat-related injury in soldiers returning from present-day
conflicts in Iraq and Afghanistan and consequently, has been
described as the “signature injury of war” (Shenton et al., 2012).
The diagnosis of mTBI remains particularly challenging due to
the usual lack of abnormal findings on conventional CT and MR
imaging (Shenton et al., 2012). Lack of a diagnostic test for mTBI
is problematic considering the potential for both enduring cere-
bral effects (cognitive, neurophysiological, and clinical) and for
identification of those at risk for development of CTE later in life.
Chronic traumatic encephalopathy represents a progressive
neurodegenerative disease currently diagnosed only upon autopsy
and subsequent neuropathological examination (Saulle and
Greenwald, 2012). Despite the lack of specific diagnostic crite-
ria required for pre-mortem clinical diagnosis, patients afflicted
with CTE diagnosed post-mortem are often described as suffer-
ing behavioral, cognitive, and emotional changes or impairments
prior to death (Gavett et al., 2011b; Omalu et al., 2011b; Saulle and
Greenwald, 2012). Notably, symptom development occurs follow-
ing a prolonged latency in most cases, although exceptions do
exist (Gavett et al., 2011a; Omalu et al., 2011b). The tendency for
a latent period creates a clear distinction between initial symp-
toms associated with traumatic brain injury (TBI) and the persis-
tent, long-term degeneration, much like other neurodegenerative
diseases such as Alzheimer’s disease (AD).
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Chronic traumatic encephalopathy has been diagnosed in a
broad spectrum of individuals with a history of head trauma,
although the number of and severity of impacts is often unclear,
ranging from athletes playing American football, soccer, hockey,
boxers, and wrestlers to soldiers who have received battlefield
injuries (Omalu et al., 2005, 2006, 2010a,b,c, 2011b; McKee et al.,
2009; Baugh et al., 2012; Goldstein et al., 2012; Lakhan and
Kirchgessner, 2012). Due to the variety of individuals afflicted
by CTE, emerging evidence indicates that CTE is likely more com-
mon than previously thought (Stern et al., 2011; Baugh et al.,
2012). Based on the experience of one group of investigators, a
conservative estimate of lifetime prevalence of CTE in American
football players is at least 3.7% (Saulle and Greenwald, 2012). Esti-
mates of CTE prevalence in retired professional boxers have been
as high as 20% (Lakhan and Kirchgessner, 2012). Considering the
number of individuals actively engaged in contact sports such as
football or exposed to explosive devices on the battlefield, it is
clear that CTE represents a clear public-health risk. Much of the
early work involving CTE diagnosis focused on concussion history
but recent studies have documented a potential role of repetitive
subconcussive blows as well (Omalu et al., 2010b; Baugh et al.,
2012).
NEUROPATHOLOGIC FINDINGS OF CTE
Gross
Gross neuropathologic examination of the brain in individuals
afflicted with CTE may produce a range of findings. The brain may
appear grossly normal or may show minimal lobar cortical atrophy
for age without remote cortical contusions or lacerations (Omalu
et al., 2005). There may be other non-specific gross pathologic
changes like fenestrations of the septi pellucidi, communicating
ventriculomegaly, subcortical ganglionic atrophy, cerebellar folial
atrophy, and pallor of the substantia nigra (Gavett et al., 2011b). In
general, however, the CTE brain of non-boxers is grossly normal
without evidence of focal traumatic brain injury.
The frequent lack of gross neuroanatomical changes observed
in CTE is in striking contrast to dementia pugilistica, believed
to represent a more severe form of CTE observed in boxers
(Millspaugh, 1937; Corsellis et al., 1973; Adams and Bruton, 1989;
Casson et al., 2006). Dementia pugilistica, described originally
as “punch drunk” by Martland (1928), was characterized neu-
ropathologically by Corsellis et al. (1973) based on a tetrad of
findings: (1) abnormalities of the septum pellucidum; (2) cere-
bellar and other scarring of the brain; (3) degeneration of the
substantia nigra; and (4) the presence of neurofibrillary tangles
(NFTs) in a regional manner. While some controversy exists con-
cerning identification of CTE, the work of Corsellis and colleagues
is notable in that at no point is encephalopathy defined by the pres-
ence of a fenestrated or cavum septum pellucidum and equally
important, the complete tetrad was not observed in a third of the
cases characterized as dementia pugilistica (Casson et al., 2006).
Microscopic
Microscopic investigation of CTE has focused primarily on several
factors: the presence of tau, amyloid, and presence of TAR DNA-
binding protein 43 proteinopathy as well as low grade diffuse white
matter rarefaction, microglial activation, and presence of reac-
tive astrocytes (Gavett et al., 2011b). The presence of a tauopathy,
whether it be in the form of neurofibrillary tangles (NFTs), neu-
ropil threads (NTs), or glial tangles (GTs), is a defining feature
of CTE. While other neurodegenerative diseases such as AD are
also frequently defined and/or described by the presence of tau,
CTE is clearly unique based on the topographic distribution of
tauopathy (Gavett et al., 2011b). AD is characterized by a relatively
uniform distribution of tau NFTs in layers containing large pro-
jection neurons, such as layers III and V (Gavett et al., 2011b). In
contrast, CTE is exemplified by an irregular distribution of tau in
more superficial cortical layers such as II and III. Similarly, the
progressive topographic involvement of regions of the brain as
seen in CTE differs from what is seen in other neurodegenerative
diseases like AD. While neuritic amyloid plaques are seen in AD,
neuritic amyloid plaques are not defining features of CTE, and are
less frequently seen in CTE (Gavett et al., 2011b).
Another delineating factor between AD and CTE is the presence
of neuritic beta amyloid (Aβ) plaques. Found extensively through-
out the brains of those afflicted with AD, neuritic amyloid plaques
are found in a minority of CTE sufferers. Diffuse and neuritic amy-
loid plaques are found in less than 40–45% of individuals with CTE
(Blaylock and Maroon, 2011; Gavett et al., 2011b). Additionally,
when found in CTE, amyloid plaques are more likely to be diffuse
plaques and not the typical neuritic plaques that are diagnostic of
AD (Gavett et al., 2011b). The role Aβ plays in CTE pathophysiol-
ogy, and why it is present in some brains but not others, remains
to be elucidated. Interestingly, amyloid precursor protein (APP),
which can undergo cleavage to form Aβ, accumulates following
axonal injury, and likely plays a role in plaque formation (Gavett
et al., 2011b).
Chronic traumatic encephalopathy has been recently associ-
ated, in greater than 80% of cases, with accumulation of yet
another phosphorylated protein aggregate, TDP-43 (Gavett et al.,
2011b). In some cases, TDP-43 has been found extending into the
anterior horns of the spinal cord, particularly in patients exhibiting
motor neuron disease symptoms similar to those of amyotrophic
lateral sclerosis (Gavett et al., 2011b; Stern et al., 2011). While TDP-
43 proteinopathy occurs as a primary or secondary proteinopathy
in a variety of neurodegenerative diseases, the significance of TDP-
43 proteinopathy in CTE is presently not clear. The presence of
another phosphorylated protein in aggregate form may indicate a
shared process resulting in neurodegeneration following repetitive
brain trauma (Gavett et al., 2011b). Being that TDP-43 has been
suggested to mediate the response of the neuronal cytoskeleton
following injury, brain trauma, and subsequent axonal injury may
trigger a TDP-43-mediated process involved in neurodegeneration
(Costanza et al., 2011).
The diversity of pathological findings associated with CTE, as
represented by the varied findings presented above, has begun to be
described with four distinct phenotypes emerging (Table 1; Omalu
et al., 2011a). The significance of these phenotypes with regards
to clinical correlate remains to be elucidated but it is becoming
increasingly clear that CTE represents a diverse spectrum of dis-
ease, a finding consistent with the heterogeneous nature of injury
history, genetic predisposition, and a variety of other factors.
CTE PATHOGENESIS AND PATHOPHYSIOLOGY
The pathogenesis and pathophysiology of CTE remain unclear,
as with many neurodegenerative diseases, but is believed to be
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Table 1 |The diversity of pathological findings in CTE has lead to the emergence of four distinct phenotypes.
Phenotype Cerebral cortex Subcortical nuclei/basal ganglia Brainstem Cerebellum
#1 +Sparse to frequent NFTs and NTs +With or without NFTs and NTs +Sparse to frequent NFTs and NTs +No NFTs and NTs
+No diffuse amyloid plaques
#2 +Sparse to frequent NFTs and NTs +With or without NFTs and NTs +Sparse to frequent NFTs and NTs +No NFTs and NTs
+Sparse to frequent diffuse amyloid
plaques
#3 +None to sparse NFTs and NTs +None to sparse NFTs and NTs +Moderate to frequent NFTs and NTs +No NFTs and NTs
+No diffuse amyloid plaques
#4 +None to sparse NFTs and NTs +None to sparse NFTs and NTs +None to sparse NFTs and NTs +No NFTs and NTs
+No diffuse amyloid plaques
How each phenotype correlates to the clinical condition remains unclear but the varied disease findings are consistent with the diversity of clinical exposure and
disease-related factors.
a multifactorial process initiated by brain trauma. The develop-
ment of CTE begins with subconcussive or concussive injury.
The damage is progressive and often accelerated by the num-
ber of brain injuries that occur in an individual. Initially, mTBI
causes diffuse axonal injury (DAI), which results in disruption
of axonal transport and subsequent axonal swelling. The swelling
causes a disconnection of the axons and later Wallerian degener-
ation (Johnson et al., 2012). This degenerative process, a portion
of which is referred to in the literature as immunoexcitotoxic-
ity, may lead to the development of CTE (Blaylock and Maroon,
2011). It is interesting to note that the abnormal tau and amyloid
accumulations, which are seen in CTE are peptide derivatives of
both membrane and cytoskeletal proteins, which are involved in
traumatic axonal injury following concussive and subconcussive
injury. This process is still relatively poorly understood clinically
with post-mortem studies on young adults revealing that repet-
itive head injury is associated with the formation of NFTs and
tau-based pathology surrounding vascular elements within the
cortex (Geddes et al., 1999). Consequently, it is perhaps likely
that microvascular damage plays a role in formation of the clas-
sical neuropathology associated with CTE. This is consistent with
findings from classical literature exploring dementia pugilistica in
which a large percentage of ex-boxers experienced perivascular
hemorrhages with evidence of meningeal and/or subpial siderosis
(Adams and Bruton, 1989). In addition to repetitive brain injury,
there may be other identified factors that may contribute to or
alter disease development, such as presence of certain genotypes
(Omalu et al., 2010b). Notably, anabolic steroid use had been
previously suggested as a potential contributing factor to CTE
development but the use of exogenous anabolic steroids has been
shown experimentally to not worsen mTBI (Mills et al., 2012).
While the precise pathway or mechanism via which repet-
itive brain trauma predisposes to CTE development is poorly
elucidated, Blaylock and Maroon (2011) posit a logical process
via which immunoexcitotoxicity mediates the transition. As part
of this process, microglia are primed by initial impacts and
with sustained trauma as well as aging, undergo phenotypic
conversion from a non-destructive to destructive mode (Blay-
lock and Maroon, 2011; Saulle and Greenwald, 2012). Once
phenotype switching occurs, this pro-inflammatory state can
be maintained for prolonged periods, consistent with neu-
rodegenerative processes and emergence of hyperphosphory-
lated tau. Similarly, mild injury has been demonstrated to
damage axons due to degenerative processes, resulting in a
progressive deterioration, rather than rapidly occurring axonal
shearing. This furthers the notion of CTE as a chronic neu-
rodegenerative process, clearly distinct from the immediate
sequelae often associated with TBI (Blaylock and Maroon,
2011).
IMAGING MODALITIES FOR REPETITIVE BRAIN INJURY AND
CHRONIC TRAUMATIC ENCEPHALOPATHY
A major concern for clinicians and researchers is how to detect
small but important brain changes prior to the development of
CTE symptoms so that preventative measures can be taken or
treatments implemented, once available (Baugh et al., 2012; Saulle
and Greenwald, 2012). The obvious short term deficits seen in
concussive injuries such as loss of consciousness, post-traumatic
amnesia, and altered mental status have been historically hard to
quantify using traditional imaging modalities such as computed
tomography (CT) and magnetic resonance imaging (MRI; Difiori
and Giza, 2010; McCrory, 2011; Prichep et al., 2012). The dif-
ficulties and shortcomings of more commonly utilized imaging
techniques have led researchers and clinicians to define concussion
as a biomechanically induced brain injury with no gross anatomic
lesions (Signoretti et al., 2011). Despite the lack of gross lesions,
it is still necessary to look at diffuse and microscopic alterations
in the brain. Until recently, imaging techniques were not sophis-
ticated enough to detect the subtle changes that are the hallmark
of DAI. Clinicians have previously been forced to rely on post-
mortem tissue analysis to discover mechanisms of CTE pathology
(Lakhan and Kirchgessner, 2012). With the invention and appli-
cation of new imaging modalities, it is now possible to identify
and investigate more of the pathological changes that are a con-
sequence of mTBI. The following sections will highlight several
of the new imaging modalities that are being used successfully to
study various phenomena associated with mTBI and also promis-
ing modalities for further investigation of CTE. These modalities
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and potential strengths, as well as challenges, associated with each
are summarized in Table 2.
DIFFUSION TENSOR IMAGING
Diffusion tensor imaging (DTI) represents one of the more thor-
oughly investigated techniques for detecting axonal injury clini-
cally (Mac Donald et al., 2007; Smits et al., 2011; Shah et al., 2012;
Shenton et al., 2012) and has even been shown to correlate with
long-term outcome in preclinical rodents models of TBI (Maller
et al., 2010). Perhaps most notably, preliminary studies in retired
professional athletes subjected to repeat head trauma demonstrate
a correlation between history of concussion and DTI measures,
particularly in the callosal white matter (Gavett et al., 2011a).
How DTI-based findings are altered with age and whether these
findings correlate with neurodegenerative and behavioral changes
associated with CTE remains to be seen (Tremblay et al., 2012).
Regardless, DTI appears to be a promising technique for detect-
ing and tracking structural correlates of repetitive brain injury
(Chappell et al., 2008; Bazarian et al., 2012; Bennett et al., 2012;
Hutchinson et al., 2012; Li et al., 2012), including those believed
to be specific to CTE.
FUNCTIONAL MAGNETIC RESONANCE IMAGING
Functional magnetic resonance imaging (fMRI) is unique amongst
the various imaging modalities discussed within this work due
to the ability to provide insight into functional alterations, par-
ticularly working memory, and anatomic or structural changes
simultaneously. The capability to measure brain-behavior rela-
tionships has proved useful in other neurodegenerative diseases
and appears promising for further investigation of CTE-related
changes (Gavett et al., 2011a). Based on blood oxygen level depen-
dent (BOLD) signal, fMRI is advantageous in that serial scans
can be administered without exposure to harmful ionizing radi-
ation (Sanchez-Carrion et al., 2008). This is particularly useful
for fMRI-based studies as baseline measurements are required for
comparison due to inter-individual variability (Rosenbaum and
Lipton, 2012). Following exposure to head trauma, deficits on
fMRI are apparent in both concussive and subconcussive injury
groups with concussive injury producing a more severe deficit
(Talavage et al., 2010; McDonald et al., 2012). Importantly, studies
utilizing both fMRI and ImPACT for neuropsychological testing
(NPT) have revealed deficits in working memory, even in the group
sustaining only subconcussive impacts, and these deficits appear
Table 2 | Numerous imaging modalities may provide insight into the development or tracking of CTE.
Imaging modality Potential strengths Potential weaknesses References of interest
Diffusion tensor imaging (DTI) +Radiologic and clinical deficits may
correlate well
+May be time-intensive if
tractography required
Henry et al. (2011a), Gavett et al.
(2011a), and Rutgers et al. (2008)
+Correlation between concussion history
and DTI measures
Functional magnetic resonance
imaging (fMRI)
+Real-time assessment of brain activity
and function
+Shown deficits in subconcussive injury
+Likely requires baseline
scan for comparison
Gavett et al. (2011a), Talavage et al.
(2010), McDonald et al. (2012),
Breedlove et al. (2012), and
Henninger et al. (2007)
Magnetic resonance
spectroscopy (MRS)
+Insight into pathophysiology of CTE +Difficulty distinguishing
between natural changes with
aging and those of injury
Henry et al. (2010), Kleindienst et al.
(2005), Lin et al. (2010, 2012); Gavett
et al. (2011a), and Tremblay et al.
(2012)
+Shown persistent changes in professional
athletes
+Metabolites may correlate with pathology
and function
Positron emission tomography
(PET)
+Identification of brain regions exhibiting
decreased metabolism
+Exposure to radioactive
isotopes may limit repeat
scans
Venneti et al. (2007), Provenzano
et al. (2010), Wagner (2012), and
Small et al. (2006)+May measure tau deposition in CTE
Single photon emission
computer tomography (SPECT)
+Abnormalities in perfusion visualized in
boxers with repeat trauma exposure
+SPECT fails to predict
neuropsychological deficits
Kemp et al. (1995) and Lin et al.
(2012)
Susceptibility weighted imaging
(SWI)
+Can map blood-brain barrier disruption
and tau deposition
+Predictive ability limited in
adults
Baugh et al. (2012), Kou et al.
(2009), Ashwal et al. (2006), and
Gavett et al. (2011a)+Shown to predict outcome in pediatric
patients post-injury
+Can detect microhemorrhages with DTI
Electroencephalography (EEG) +Components of P300 such as P3a/P3b
altered chronically post-concussion
+Minimal investigation
outside of boxing
Costanza et al. (2011) and Gavett
et al. (2011a)
+Low cost +Analysis difficult
Each modality exhibits potential strengths and weaknesses, presented here, affecting its viability for further CTE-related research.
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to be related to the number of impacts rather than the magni-
tude of any one impact (Breedlove et al., 2012). Furthermore, in
a preclinical model of TBI, fMRI response was diminished acutely
and correlated with functional deficits based on the forepaw place-
ment test (Henninger et al., 2007). The use of fMRI for assessing
the more subtle deficits produced by repetitive subconcussive
impacts warrants further investigation, and in particular, longitu-
dinal studies investigating the persistence of deficits on fMRI and
the likelihood of further development for detecting, diagnosing,
and tracking CTE.
MAGNETIC RESONANCE SPECTROSCOPY
Magnetic resonance spectroscopy (MRS) is a non-invasive method
that measures brain chemistry associated with DAI and neuronal
injury (Gavett et al., 2011a; Shenton et al., 2012). It is sensitive for
changes occurring with age, mTBI, and mild cognitive impairment
(MCI; Tshibanda et al., 2009). As an imaging modality, 1H MRS
is used to detect changes in N -acetylaspartate (NAA), myoinositol
(mI), choline, lactate, and adenosine triphosphate (ATP) produc-
tion in specific ROI. NAA is a neuronal marker and is reported as
a NAA:creatinine ratio. Other markers that may prove useful in
neural injury include mI, a glial marker (Signoretti et al., 2010),
choline-based compounds, indicative of membrane integrity, and
lactate, an indirect marker for ischemia (Signoretti et al., 2010).
The metabolite levels in an injured brain are compared to levels
in a healthy brain for analysis (Vagnozzi et al., 2010). A decrease
in NAA and ATP is indicative of reversible neuronal and mito-
chondrial dysfunction (Henry et al., 2011b). An elevation of the
NAA:creatinine ratio indicates persistent damage following mTBI
(Signoretti et al., 2011). H2O is often measured as an internal
control in the patient during imaging (Tremblay et al., 2012). By
monitoring the metabolites and H2O, the progress of a patient can
be tracked longitudinally (Bigler and Maxwell, 2012). It is even
possible to detect changes in the brain prior to onset of symp-
toms such as in subconcussive injuries (Henry et al., 2010). Fur-
thermore, metabolite levels remain altered long after symptoms
subside, which gives credence to the idea of long-term degenera-
tion occurring and presence of a latent period (Kleindienst et al.,
2005). As MRS utilizes current clinical MR scanners and does
not administer ionizing radiation to the patient, MRS may rep-
resent an ideal imaging modality for long-term studies requiring
repeated measurements. Furthermore, a preliminary study con-
ducted by Lin and colleagues demonstrated persistent changes in
Cho and Glx in 5 professional athletes, aged 31–54 years. Specifi-
cally, both Cho and Glx were significantly increased as compared
to controls (Lin et al., 2010, 2012; Gavett et al., 2011a). Addi-
tionally, studies have demonstrated changes in mI consistent with
MCI literature that correlate with NFT count in AD brains upon
pathological examination (Tremblay et al., 2012). Consequently,
understanding the effect of repetitive brain injuries on mI levels
over time may be of interest for future investigation due to the
strong correlation with episodic memory deficits observed in for-
merly concussed athletes (Tremblay et al., 2012). Based on this
evidence, MRS appears promising for not only elucidation of CTE
pathophysiology but also tracking the effects of repetitive brain
trauma longitudinally. In this manner, MRS may also be useful for
the diagnosis of CTE in effected individuals.
POSITRON EMISSION TOMOGRAPHY
Positron emission tomography (PET) can be used to detect meta-
bolic rates in a variety of tissues of interest, including the brain
(Price and Jones, 1995). While PET has traditionally been used in
cases of more severe injury, recent evidence indicates a potential
role in mTBI (Mase et al., 2004; Venneti et al., 2007). In box-
ers, hypometabolism was observed in regions likely affected by
impacts to the side of the head such as the portion of the frontal
lobe anterior to Broca’s area (Provenzano et al., 2010). Similarly,
hypometabolism was observed in the posterior cingulate cortex
and posterior parietal lobes (Provenzano et al., 2010). In other
patients afflicted with TBI, hypometabolism may be seen com-
monly in the anterior temoporal lobe and orbitofrontal lobe due
to rapid acceleration-deceleration mechanisms (Provenzano et al.,
2010). Other promising developments in PET imaging include
the development of ligands specific for disease states such as
AD. For example, Pittsburgh compound B selectively binds Aβ
whereas others under development non-selectively bind both Aβ
and tau (Gavett et al., 2011a). While Aβ is not diagnostic for CTE,
this technology appears potentially promising for the imaging of
CTE should tau-specific compounds be identified. Furthermore,
recent studies using F18 DDNP glucose-PET, conducted by Dr.
Gary Small at UCLA, show promise for identifying tau protein
deposition in the form of NFT’s in subjects with potential CTE
(Wagner, 2012). F18 DDNP glucose-PET allows for labeling of
both plaques and tangles, as has been shown in cases of MCI as
well as AD, making this technique exceptionally promising in iden-
tifying characteristic pathological features of CTE as they develop
pre-mortem (Small et al., 2006). This effort is significant in that
it could potentially allow, for the first-time ever, the diagnosis of
CTE pre-mortem (Small, 2012). Similarly, identification of NFT’s
following brain injury would provide substantial insight into the
timing of development and pathophysiology of CTE.
SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY
Single photon emission computer tomography (SPECT), simi-
lar to PET in the use of radionuclides, can be used for mea-
surement of cerebral perfusion and has been shown to detect
abnormalities in 41% of amateur boxers in comparison to 14%
of controls. Furthermore, abnormalities were generally singu-
lar in the control group yet multiple in the group of boxers
subjected to repetitive brain trauma (Kemp et al., 1995). While
SPECT has not been utilized in studies of CTE, CTE is asso-
ciated with amyloid protein deposition in a significant number
of cases and amyloid is notably largely perivascular in depo-
sition, particularly in regions of abnormal vasculature, which
could account for abnormal findings on SPECT (Kemp et al.,
1995). It has also been correlated with functional deficits revealed
on NPT. Specifically, NPT strongly predicts diminished perfu-
sion on SPECT but the inverse is not true (Lin et al., 2012).
The reasons for this mismatch are currently unknown but may
be due to SPECT being obtained at a resting state while NPT
requires neural activity and processing (Lin et al., 2012). In spite
of this lack of correlation and lack of specificity when consider-
ing other disease conditions, SPECT has clear value in recovery
prognostication based on previously reported findings (Lin et al.,
2012).
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SUSCEPTIBILITY WEIGHTED IMAGING
Susceptibility weighted imaging (SWI) is used to detect microhem-
orrhages, the intact structure of the venous system, and oxygen sat-
uration following neurotrauma (Shen et al., 2007). Microhemor-
rhages, venous thrombosis, and ischemia are common secondary
injuries following mTBI (Aiken and Gean, 2010). Furthermore,
the extent of blood-brain barrier (BBB) disruption and perivascu-
lar tau deposition can be mapped with SWI (Baugh et al., 2012).
Tau accumulates in the brain during the progression of CTE (Stern
et al., 2011). The imaging technique works by taking phase data
from a T2∗ weighted MRI and creating a second mapped image.
This image allows both blood oxygen levels and the amount of
deoxyhemoglobin to be measured (McCrea et al., 2008). It also
localizes concentrations of paramagnetic iron and detects areas
of iron translocation (Cheng et al., 2010). Iron deposition may
play a role in CTE symptom manifestation (Zhang et al., 2010).
The images produced with SWI are highly functional, velocity-
compensated, and gradient echoed (Meoded et al., 2012). When
used with DTI, SWI can accurately show which areas of white
matter are damaged by microhemorrhages (Kou et al., 2009). This
modality offers a unique tool to detect areas of injury early, and
provides clinicians with information on how to manage the care of
the patient, particularly in children in which SWI has been shown
to predict future outcomes following injury (Ashwal et al., 2006;
Gavett et al., 2011a). Unfortunately, the predictive ability is more
limited in adults at present but necessitates further study (Gavett
et al., 2011a).
ELECTROENCEPHALOGRAPHY
Electroencephalography (EEG) has been used to demonstrate
mental processing impairment in 12 professional concussed box-
ers based on increased P300 latency and lessened amplitude. P300
has been identified as a cognitive event-related potential (ERP)
with a novel amplitude and latency, making it a potentially suit-
able measure of brain processing ability. Similarly, investigators
have demonstrated altered components of P300, such as P3a/P3b,
decades after concussion in older athletes with a history of past
concussion compared to controls (Costanza et al., 2011; Gavett
et al., 2011a). Based on these findings, EEG may have utility in
assessing long-term cognitive effects associated with concussion
and therefore, may be useful in identifying those predisposed to
CTE development.
FUTURE DIRECTIONS
Advances in imaging technology and improved access provide
nearly limitless opportunities for both understanding the patho-
physiology and diagnosis of CTE pre-mortem. As such, it may be
possible to initiate both treatments and preventive measures prior
to emergence of CTE. Many challenges remain such as clarifying
the role of subconcussive injury in CTE development and how
to most readily identify suspected subconcussive injuries on the
athletic or battlefield. By utilizing techniques such as MRS and
fMRI, pathology can be correlated with functional deficits and
hopefully lead to more appropriate identification and monitoring
of those with suspected injuries, regardless of severity. Other chal-
lenges such as the need for baseline measurements remain to be
overcome as well but clearly warrant additional investigation.
BIOMARKERS FOR CTE: A NEW FRONTIER
As discussed in previous sections modern imaging techniques are
one way by which diagnosing and tracking the progression of CTE
may be feasible in the near future. Unfortunately, access and eco-
nomic issues associated with imaging techniques may somewhat
limit their ultimate usefulness in the diagnosis of CTE, especially
during the acute phases of injury. With CTE potentially being a
large public-health issue, a simple and cost effective manner to
diagnose and possibly track progression of the disease is crucial
(Baugh et al., 2012).
Biomarkers represent one method by which CTE may one day
be diagnosed. Additionally, it may be possible to track disease
severity and progression through the use of a biomarker(s). Ideally,
a potential biomarker for CTE would be minimally invasive, have
diagnostic potential and would correlate to disease severity, allow-
ing care providers to track progression of the disease. It should be
sensitive enough to detect the disease and when used in conjunc-
tion with clinical evidence of CTE symptoms and a past history of
repeated head injuries, allow for a diagnosis. As described above,
there is currently no accepted method of diagnosing CTE until
post-mortem pathological analysis has been conducted (Baugh
et al., 2012). A readily available biomarker with the aforemen-
tioned traits would give practitioners a useful tool for the diagnosis
and tracking of patients suffering from CTE.
Currently there is a paucity of studies aimed at determining a
biomarker(s) specifically for CTE. Many studies aimed at eluci-
dating biomarkers for TBI and other types of neurotrauma have
been conducted. One difficult aspect of searching for a CTE bio-
marker is that CTE symptomology can be similar to a variety of
other neurologic disorders. This may add a layer of complexity
to conducting human clinical studies in an attempt to discover
suitable biomarkers. The neuropathology of CTE, however, is not
distinctly different, as hyperphosphorylated tau and TDP-43 depo-
sition are found in a variety of neurodegenerative diseases outside
CTE (McKee et al., 2010; Baugh et al., 2012; Saulle and Greenwald,
2012). Additionally, recent reports indicate that CTE may be asso-
ciated with symptomology similar to ALS, further complicating
the likelihood of clinical diagnosis without improved diagnostic
tests (McKee et al., 2010). These reports emphasize the need for a
biomarker with high specificity that can delineate CTE from other
neurologic disorders.
There are two primary body fluids where readily attainable
biomarkers of CTE may be located. These include the cerebral
spinal fluid (CSF) and the blood. Blood or plasma samples have
the distinct advantage of being minimally invasive and easy to
obtain. CSF samples, however, are in more direct contact with the
CNS and may confer an advantage in this regard to the deter-
mination of suitable biomarkers for CTE. Routine use of CSF in
the diagnosis or tracking of CTE presents several obvious prob-
lems associated with obtaining CSF samples. Therefore, ideally
a biomarker aimed at detecting CTE in the periphery would be
found in serum or plasma samples obtained via venipuncture.
As discussed above, currently there is a lack of primary studies
aimed at the elucidation of biomarkers in either one of these
body fluids for CTE. However, several studies have been con-
ducted in the realm of TBI and mTBI and these will be discussed
herein.
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It may be possible that biomarkers in development for TBI
may be useful during the acute injury phase of patients at risk for
CTE. The repeated concussive and subconcussive blows that result
in CTE may alter levels of particular biomarkers studied for TBI
immediately following these events. The tracking of these acute
changes, although not specific to CTE, may give healthcare profes-
sionals insight into those patients at the greatest risk for developing
CTE later in life. Equally important though, is the potential utility
for biomarker surveillance in patients with known or suspected
post-concussion syndrome.
Many studies that have been conducted aimed at determining
a biomarker for TBI or mTBI in the plasma or serum. A study
conducted by Mondello et al. has determined that glial neuronal
ratio (GNR), characterized as the ratio between glial fibrillary
acidic protein (GFAP) and ubiquitin carboxy-terminal hydrolase-
L1 (UCH-L1) in the serum of TBI patients is characteristic of the
type of TBI injury, focal vs. diffuse (Mondello et al., 2012). It was
noted by Mondello et al. (2012) that their studies may have impli-
cations for diagnosis in TBI patients in the early acute phases of
injury, however whether these results would have implications for
CTE patients has yet to be determined. It is possible that after mul-
tiple concussive or subconcussive blows to the head that the GNR
may be altered and may offer insight into the extent of injury and
potential for later development of CTE.
Several other studies aimed at elucidating valuable biomarkers
for TBI in the serum have been conducted and may offer insight
into the production of a biomarker(s) specific to CTE. It has been
reported that plasma bilirubin levels in TBI patients are elevated
on days subsequent to injury (Dohi et al., 2005). Unfortunately,
this study only determined bilirubin levels up to 4 days post-injury.
The determination as to whether the increases in plasma bilirubin
remain elevated for a significant amount of time post-injury or
whether it is specific to the acute injury phase has yet to be made.
Additionally, the determination as to whether bilirubin concentra-
tions in the plasma would be elevated in patients at risk for CTE
has also yet to be made.
Another intriguing potential serum biomarker for CTE may be
the protein neuron-specific enolase. Zetterberg et al. (2009) have
shown that this protein is increased in the serum of boxers as com-
pared to healthy controls after the boxers abstained from boxing
for a period of 2 months. Interestingly, elevated levels of neuron-
specific enolase were detected 2 months after a non-participatory
period of boxing, however other biomarker candidates for CTE
such as S-100B, brain-derived neurotrophic factor (BDNF), and
heart-type fatty acid binding protein (H-FABP) were found to be
unchanged (Zetterberg et al., 2009). These results indicate that
neuron-specific enolase may be one protein biomarker that has
the potential for use as a diagnostic tool. It is possible that neuron-
specific enolase remains elevated for an extended time period
after injury and may be a useful tool for diagnostic purposes in
athletes and patients who have suffered multiple concussive and
subconcussive blows to the head.
An area of biomarker research that has received much attention
is the field of microRNA. It is possible that potential biomark-
ers for CTE may not only be protein-based in nature. A recent
report by Balakathiresan et al. (2012) has shown that levels of
microRNA let-7i are elevated post-blast-induced TBI in both the
CSF and the serum of rats exposed to a model of this type of
TBI. Additionally, this group showed that the expression of five
microRNA’s were altered post-blast TBI in the serum of these
animals (Balakathiresan et al., 2012). These included let-7i, miR-
122, miR-200b, miR-340-5p, and miR-874 (Balakathiresan et al.,
2012). Further study is needed in both animal models, as well as
humans, to validate the potential for using microRNA’s as poten-
tial biomarkers for TBI and possibly CTE. Although this study
was conducted using a blast TBI animal model, a recent report
has shown that this model produces pathology similar to that seen
in CTE and models similar to this may be viable animal mod-
els for the study of CTE (Goldstein et al., 2012). The production
of validated animal models could greatly aid in the discovery of
biomarkers aimed at detecting CTE and the production of poten-
tial clinical therapies for treating CTE. Other studies have also
successfully identified RNA-based biomarkers for mTBI based on
both micro- and snoRNA in peripheral blood mononuclear cells
(PBMCs). Using a panel of three markers, veterans that experi-
enced mTBI were detected with 89% accuracy, 82% selectivity,
and 78% specificity (Pasinetti et al., 2012). Future studies utilizing
both animal models as well as clinical samples may reveal addi-
tional RNA-based molecules that may be viable biomarkers for
detecting and possibly tracking CTE.
One particularly interesting report recently published, stud-
ied a variety of biomarkers aimed at detecting TBI and mTBI in
Olympic boxers with an extended history of many bouts (Neselius
et al., 2012). This study determined extent of increases in neurofil-
ament light protein (NFL), total tau (T-tau), tau phosphorylated
at threonine 181 (P-tau181), H-FABP, GFAP, S-100B, and the 42
amino acid form of amyloid β (Aβ1–42) in Olympic boxers both in
the acute phase after a bout and an extended phase of 2 weeks post-
bout and compared them to non-boxing controls. It was found that
both NFL and GFAP levels within the CSF were significantly differ-
ent from controls in both the acute and extended phase of testing
(Neselius et al., 2012). The determination as to whether either of
these correlated to injury severity was unable to be conclusively
made in this study (Neselius et al., 2012).
However, a previous study has shown that there may be a poten-
tial correlation between NFL levels in the CSF and injury severity
(Zetterberg et al., 2006). Zetterberg et al. (2006) showed that NFL,
T-tau, and GFAP were increased in the CSF of boxers and the
levels appear to be correlated to injury severity, as boxers who
received more hits in number or severity had increased levels of
these markers. Only NFL in these studies however, was increased
for an extended time period (tested at 3 months) as compared to
controls (Zetterberg et al., 2006). The extended increase in NFL
levels within the CSF post-injury may make it a viable candidate
for a biomarker for mTBI and CTE however whether levels of
NFL within the CSF correlate to later disease severity in the case of
CTE or mTBI has yet to be conclusively made. NFL levels however,
have been shown to be altered in other types of neurologic trauma
and disorders so this may ultimately decrease its viability as a tool
for detecting, diagnosing, and tracking CTE disease progression
(Avsar et al., 2012; Tortelli et al., 2012).
Although levels of proteins such as NFL and tau may not be spe-
cific with regards to CTE, a battery of various biomarker proteins
combined with patient history and imaging studies (discussed
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in previous sections) may result in the ability to make a pre-
mortem diagnosis of CTE via a reference fractional laboratory
index using a high throughput analytical system. In this respect,
a combined battery of proteins such as tau, GFAP, NFL, S100-
B, and bilirubin may offer more accurate quantitative data with
regards to a patients risk for developing CTE and when combined
with other modalities of relevant clinical data, may be used as
even more accurate diagnostic indicators at some point in the
future.
LINKING PATHOPHYSIOLOGY TO IMAGING AND BIOMARKER
DISCOVERY
Perhaps the greatest challenge concerning development of bio-
markers or imaging modalities for prevention, diagnosis, and
prognosis of CTE is the current lack of well-elucidated disease
pathophysiology. Consequently, few clearly identifiable and spe-
cific disease markers have been identified. Without first under-
standing disease development more clearly, likely via both clinical
research and utilization of animal models of repetitive brain
FIGURE 1 | Imaging and biomarker studies may be useful in improving understanding of the role of repetitive concussive and subconcussive injury in
disease development. Two experimental paradigms are presented representing a potentially more ideal, but costly, scenario (A) and the more cost-conscious
approach (B).
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trauma, logical discovery of CTE-associated markers appears
unlikely. Recent work has demonstrated the presence of CTE-like
neuropathology in wild-type mice following single-blast exposure
and increased formation of NFTs in a transgenic mouse model
following repetitive injury (Yoshiyama et al., 2005; Goldstein et al.,
2012). In a single-injury experiment, again using transgenic mice
utilized in AD models, tau and amyloid-β accumulation was
accelerated (Tran et al., 2011). Similarly, studies have shown the
presence of phosphorylated tau and amyloid-βmonths after initial
fluid percussion injury in the genetically unmodified rat (Hoshino
et al., 1998).
Despite the present lack of clear elucidation of disease patho-
physiology, certain imaging techniques such as MRS, fMRI, and
tau-specific labeling compounds in PET, have begun and will likely
continue to provide insight into CTE development via longitudinal
changes in neurologic function and health via a variety of markers.
Similarly, work in other disease conditions that allows for imaging
of activated microglia, consistent with the notion of immunoex-
citotoxicity, may provide further insight into disease development
and progression (Venneti et al., 2007).
In addition to assisting in the diagnosis and prognosis of
patients suffering from CTE, continued improvements in imag-
ing and biochemical assays associated with CTE identification may
promote risk factor identification and provide insight into periods
of increased risk. For example, the role of age at time of impact
and associated brain trauma in disease development is unclear.
Understanding this issue warrants further investigation as neu-
ropathologic changes associated with CTE have been found in an
asymptomatic 18-year-old high school football player and conse-
quently, age at time of first head injury may contribute to CTE
incidence (Saulle and Greenwald, 2012).
CONCLUSION
Chronic traumatic encephalopathy is an emerging public-health
concern due to disease prevalence likely higher than previously
recognized and continued popularity of contact sports as well as
involvement in military combat that places soldiers at risk for
explosive blasts and subsequent TBI. As CTE represents a dev-
astating deterioration of neurologic function, a clear need for
improved diagnostic and prognostic tests exists. To accommodate
this need, as well as more clearly elucidate disease pathophys-
iology, imaging, and/or biomarker-based tests are required. We
propose a potential work-flow for implementation of both imag-
ing and biomarker-based studies for improving the understanding
of the role concussive and subconcussive impacts play in long-
term disease development (Figure 1). While the specifics remain
open to interpretation, obtaining pre-injury exposure studies as
well as after a suspected or confirmed injury parameters is likely
to provide further insight into the effects of TBI. It is only by
more accurately identifying CTE pre-mortem and studying dis-
ease progression and mechanisms that we can establish improved
therapeutic approaches.
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